Oral GLP-1 Drug Orforglipron Slashes Blood Pressure, Cholesterol and Inflammation in Phase 2 Trials

Cardiovascular disease remains the leading cause of death in people with type 2 diabetes (T2D) or obesity, who face 2–3 times higher CVD incidence than the general population. Injectable GLP-1 receptor agonists like semaglutide and liraglutide have established cardiovascular outcome benefits, but oral delivery remains challenging. Orforglipron is a novel small-molecule, non-peptide GLP-1 receptor agonist that can be taken orally once daily without food restrictions — a key practical advantage over oral semaglutide, which requires strict dosing conditions. This exploratory analysis examined whether orforglipron improves the constellation of cardiovascular risk biomarkers that predict MACE outcomes.

The study drew on two completed Phase 2 randomized controlled trials. The T2D trial (NCT05048719) enrolled 383 participants, with 361 providing evaluable biomarker data. Participants had a mean age of 59 years, mean HbA1c of 8.1%, and mean BMI of 35.3 kg/m². They received once-daily orforglipron at 3, 12, 24, 36, or 45 mg, once-weekly subcutaneous dulaglutide 1.5 mg, or placebo for 26 weeks. The obesity trial (NCT05051579) enrolled 272 participants without diabetes, with 234 providing evaluable data; mean age was 54 years and mean BMI was 37.9 kg/m². These participants received orforglipron 12–45 mg or placebo for 36 weeks alongside lifestyle counseling. Statistical analysis used mixed model repeated measures and ANCOVA with no adjustments for multiple comparisons, consistent with the exploratory nature of the analyses.

In the T2D trial, orforglipron produced significant placebo-adjusted reductions in systolic blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP. LDL cholesterol was reduced by approximately 5–10% versus placebo across active doses, triglycerides dropped by roughly 10–20%, and hsCRP fell by approximately 25–40% at higher doses. ApoB and ApoC3 reductions were also statistically significant and clinically meaningful, suggesting reduced atherogenic lipoprotein burden beyond what LDL alone captures. IL-6 showed directional improvement but results were variable across doses.

In the obesity trial, similar patterns emerged. Orforglipron significantly reduced blood pressure, LDL, triglycerides, ApoB, ApoC3, and hsCRP versus placebo over 36 weeks. Notably, a key dose-response finding in both studies was that the magnitude of improvement in blood pressure, lipid parameters, and most biomarkers was largely achieved at the 12 mg dose, with limited additional benefit at 24, 36, and 45 mg. Dulaglutide in the T2D trial produced broadly comparable improvements, lending external validity to the orforglipron biomarker findings. NT-proBNP did not show significant changes, suggesting no major effect on cardiac wall stress at these doses.

These findings are clinically significant because they position orforglipron as a potential cardiovascular risk-reducing agent in pill form — a format that could dramatically expand access compared to injectables. The biomarker profile mirrors that seen with injectable semaglutide and liraglutide, which preceded their demonstrated MACE reductions. The consistency of effects across both diabetic and non-diabetic obese populations suggests GLP-1 receptor agonism — not just glucose lowering — drives cardiovascular benefit. However, this remains an exploratory analysis from Phase 2 trials without hard cardiovascular endpoints, Eli Lilly funded the research, and Phase 3 outcomes trials are underway but results are not yet available.